IDENTIFICATION OF HUMAN IMMUNODEFICIENCY VIRUS ANTIGENIC SUBTYPES WITH RELEVANCE TO AIDS VACCINES: A PROTOTYPE STUDY NLM AIDSLINE Important note: Information in this article was accurate in 1989. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


IDENTIFICATION OF HUMAN IMMUNODEFICIENCY VIRUS ANTIGENIC SUBTYPES WITH RELEVANCE TO AIDS VACCINES: A PROTOTYPE STUDY

Vaccines 88. New Chemical and Genetic Approaches to Vaccination: Prevention of AIDS and Other Viral, Bacterial, and Parasitic Diseases. Ginsberg H et al, eds. New York, Cold Spring Harbor Laboratory, p. 365-71, 1988.. Unique Identifier : AIDSLINE ICDB/89649783
Homsy J; Cheng-Mayer C; Tateno M; Levy JA; Cancer Res. Inst., Sch. of Medicine, Univ. of California, San; Francisco, CA 94143

Abstract: Twenty HIV isolates were tested in a prototype study for their sensitivity to neutralization by human serum. A neutralization assay measuring the reduction of HIV infectivity in peripheral blood mononuclear cell cultures was used to define the HIV subgroups. Among the 20 HIVs studied, four neutralization-specific groups were recognized. Isolates obtained from the CNS and from different geographical regions (United States, Africa, and Dominican Republic) exhibited particular differences in serum neutralization. The results were not due to differences in serum antibody titers or virus replicative titers. Moreover, the data suggest that the use of established T-cell lines for neutralization studies restricts the range of HIV variation that can be studied. The results show that HIV variants can be grouped in distinct subtypes, which differ in susceptibility to neutralization and in replicating ability. These findings suggest that an indefinite number of HIV variants do not exist and that these variants can be subgrouped in distinct subtypes. The implications for vaccine development are important; a limited number of representative HIVs could be used in combination to confer polyspecific immunoprotection. (10 Refs)
Keywords: Acquired Immunodeficiency Syndrome/*IMMUNOLOGY *Antigenic Variation Enzyme-Linked Immunosorbent Assay Human HIV/*IMMUNOLOGY HIV Antibodies/BIOSYNTHESIS HIV Antigens/*IMMUNOLOGY Neutralization Tests Vaccines, Synthetic/*IMMUNOLOGY Viral Vaccines/*IMMUNOLOGY MEETING PAPER

KWDacquiredimmunodeficiencysyndrome/KWDimmunologyKWDantigenicvariationenzyme-linkedimmunosorbentassayhumanhiv/KWDimmunologyhivantibodies/biosynthesishivantigens/KWDimmunologyneutralizationtestsvaccines,synthetic/KWDimmunologyviralvaccines/KWDimmunologymeetingpaper
890330
M8930533

Copyright © 1989 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1989. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1989. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .